Eptinezumab: all 27 studies that test it
Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingNCT07655440Phase 4
- Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionNot yet recruitingNCT07645833Phase 3
- Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)Not yet recruitingNCT07191145Phase 3
- Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency ContextEnrolling by invitationNCT06428838Phase 3
- A Study of Eptinezumab in Pediatric Participants With Episodic MigraineRecruitingNCT05897320Phase 3
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineRecruitingNCT05164172Phase 3
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigraineRecruitingNCT04965675Phase 3
- A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheCompletedNCT05452239Phase 4Results posted
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedNCT05284019Phase 4Results posted
- A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)CompletedNCT05064397Phase 3Results posted
- Eptinezumab in Participants With Episodic Cluster HeadacheCompletedNCT04688775Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive TreatmentsCompletedNCT04418765Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of MigraineCompletedNCT04152083Phase 3Results posted
- An Open Label Trial of ALD403 (Eptinezumab) in Chronic MigraineCompletedNCT02985398Phase 3Results posted
- Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic MigraineCompletedNCT02974153Phase 3Results posted
- A Multicenter Assessment of ALD403 in Frequent Episodic MigraineCompletedNCT02559895Phase 3Results posted
- A Multicenter Assessment of ALD403 in Chronic MigraineCompletedNCT02275117Phase 2Results posted
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsCompletedNCT06701526Phase 4
- A Study of CGRP Monoclonal Antibody to Treat Diabetic NeuropathyWithdrawnNCT05937152Phase 2
- Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.CompletedNCT05635604Not applicable
- Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in JapanCompletedNCT05064371Phase 3
- Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese SubjectsCompletedNCT05045781Phase 1
- Eptinezumab as Preventive Treatment of Migraine in Adults With MigraineCompletedNCT04921384Phase 3
- Eptinezumab in Adults With Migraine and Medication Overuse HeadacheCompletedNCT04772742Phase 3
- A Study in Children and Young People With Migraine to Learn What the Body Does to EptinezumabCompletedNCT04537429Phase 1
- Eptinezumab in Healthy Japanese SubjectsCompletedNCT04336449Phase 1
- Safety, Efficacy and Pharmacokinetics of ALD403CompletedNCT01772524Phase 1